This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L. G. Articles by Budman, D. R. Search for Related Content PubMed Articles by Wang, L. G. Articles by Budman, D. R.

Down-Regulation of Prostate-specific Antigen Expression by Finasteride through Inhibition of Complex Formation between Androgen Receptor and Steroid Receptor-binding Consensus in the Promoter of the PSA Gene in LNCaP Cells¹

Department of Medicine, New York University, North Shore University Hospital, Manhasset, New York 11030

As a specific competitive inhibitor of 5-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone, finasteride is being extensively used for the treatment of benign prostatic hyperplasia and in experimental settings for prostate cancer. In this study, we showed that finasteride markedly inhibited prostate-specific antigen (PSA) secretion and expression.

The promoter of the PSA gene contains several well-known cis-regulatory elements. Among them, steroid receptor-binding consensus (SRBC) has been identified as a functional androgen-responsive element. Our previous study showed that PSA was not only present in conditioned medium of the PSA-positive LNCaP cells but was also detectable in small amounts in PSA-negative cell lines, PC-3 and DU-145 (L. G. Wang et al., Oncol. Rep., 3: 911–917, 1996). A strong correlation between binding of nuclear factors to SRBC and the level of PSA present in the conditioned medium and cell extracts was found in these three cell lines, whereas no such correlation with binding was obtained using Sp1 oligonucleotide as a probe. Binding of LNCaP cell nuclear proteins to SRBC was diminished when the cells were exposed to 25 µM finasteride, at which concentration 50% of both PSA mRNA and protein were inhibited. As a major component of DNA-protein complexes, the level of androgen receptor was dramatically decreased in the cells treated with finasteride.

Our data indicate that inhibition of complex formation between SRBC and nuclear proteins due to the remarkable decrease in the level of androgen receptor plays a key role in the down-regulation of PSA gene expression by finasteride in LNCaP cells.

¹ This study was supported by the Don Monti Memorial Research Foundation.

² To whom requests for reprints should be addressed, at Don Monti Division of Hematology and Oncology, Department of Medicine, New York University School of Medicine, North Shore University Hospital, Manhasset, NY 11030. Phone: (516) 562-8906; Fax: (516) 562-8950.

Received 9/24/96. Accepted 12/20/96.

This article has been cited by other articles:

				L. G. Wang, E. M. Johnson, Y. Kinoshita, J. S. Babb, M. T. Buckley, L. F. Liebes, J. Melamed, X.-M. Liu, R. Kurek, L. Ossowski, et al. Androgen Receptor Overexpression in Prostate Cancer Linked to Pur{alpha} Loss from a Novel Repressor Complex Cancer Res., April 15, 2008; 68(8): 2678 - 2688. [Abstract] [Full Text] [PDF]

				L.G. Wang, X.M. Liu, and J.W. Chiao Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate Carcinogenesis, October 1, 2006; 27(10): 2124 - 2132. [Abstract] [Full Text] [PDF]

				J. T. E. Lim, M. Mansukhani, and I. B. Weinstein Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells PNAS, April 5, 2005; 102(14): 5156 - 5161. [Abstract] [Full Text] [PDF]

				S. Sarfaraz, F. Afaq, V. M. Adhami, and H. Mukhtar Cannabinoid Receptor as a Novel Target for the Treatment of Prostate Cancer Cancer Res., March 1, 2005; 65(5): 1635 - 1641. [Abstract] [Full Text] [PDF]

				L. J. Schmidt, H. Murillo, and D. J. Tindall Gene Expression in Prostate Cancer Cells Treated With the Dual 5 Alpha-Reductase Inhibitor Dutasteride J Androl, November 1, 2004; 25(6): 944 - 953. [Abstract] [Full Text] [PDF]

				J. T. E. Lim, G. A. Piazza, R. Pamukcu, W. J. Thompson, and I. B. Weinstein Exisulind and Related Compounds Inhibit Expression and Function of the Androgen Receptor in Human Prostate Cancer Cells Clin. Cancer Res., October 15, 2003; 9(13): 4972 - 4982. [Abstract] [Full Text] [PDF]

				Y.-S. Zhu, L.-Q. Cai, X. You, J. J. Cordero, Y. Huang, and J. Imperato-Mcginley Androgen-Induced Prostate-Specific Antigen Gene Expression Is Mediated via Dihydrotestosterone in LNCaP Cells J Androl, September 1, 2003; 24(5): 681 - 687. [Abstract] [Full Text] [PDF]

				G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553. [Abstract] [Full Text] [PDF]

				Long. G. Wang, L. Ossowski, and A. C. Ferrari Overexpressed Androgen Receptor Linked to p21WAF1 Silencing May Be Responsible for Androgen Independence and Resistance to Apoptosis of a Prostate Cancer Cell Line Cancer Res., October 1, 2001; 61(20): 7544 - 7551. [Abstract] [Full Text] [PDF]

				S. C. Dixon, K. B. Knopf, and W. D. Figg The Control of Prostate-Specific Antigen Expression and Gene Regulation by Pharmacological Agents Pharmacol. Rev., March 1, 2001; 53(1): 73 - 92. [Abstract] [Full Text] [PDF]

				X. Zi and R. Agarwal Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention PNAS, June 22, 1999; 96(13): 7490 - 7495. [Abstract] [Full Text] [PDF]